At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
CFZ533drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease
In Brief
A Phase 2 clinical trial evaluating CFZ533 for Graves' Disease. Completed, enrolled 15 participants across 3 sites in 2 countries.
Detailed Summary
An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraves' Disease
CountriesGermany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionApr 2017
TodayJul 2026
First PostedMar 18, 2016
Enrollment StartApr 19, 2016
Primary CompletionApr 24, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.3 years ago
Interventions
CFZ533drug
CFZ533 intravenously over approximately one hour